

TiGenix publishes transparency notification pursuant to Article 14 of the Law of May 2, 2007

Leuven (Belgium) – December 8, 2015 – TiGenix NV (Euronext Brussels: TIG) publishes today a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.

It concerns a notification by the related companies Grifols S.A. / Gri-Cel S.A. (both with address at Avenida de la Generalitat 152, 08174 Sant Cugat del Vallès, Barcelona, Spain), following the passive crossing below the 20% threshold on November 27, 2015, after which the participations of these companies were as follows (compared to the denominator of 172,338,663 shares as at November 27, 2015):

- Grifols S.A.: 0 shares (0%),
- Gri-Cel S.A.: 34,188,034 shares (19.84%),
- Total: 34,188,034 shares (19.84%).

The chain of controlled undertakings through which the holdings are effectively held, is as follows: Grifols, S.A. controls Instituto Grifols, S.A. and Instituto Grifols, S.A. controls Gri-Cel, S.A.

Finally, Grifols Worldwide Operations Limited holds 250 convertible bonds with expiration date March 6, 2018 and conversion period from April 16, 2015 until February 20, 2018. If all 250 convertible bonds are converted at the initial conversion price, Grifols Worldwide Operations Limited will acquire 26,556,192 voting rights.

For further details regarding this notification, we refer to our website: <http://www.tigenix.com/en/page/26/shareholders>.

For more information:

Claudia D'Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta@tigenix.com

About TiGenix

TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived stem cell technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn's disease patients. Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI). In addition, the second product candidate from the cardiac stem cell-based platform acquired

TIGENIX

from Coretherapix, AlloCSC-02, is being developed in a chronic indication. TiGenix also developed ChondroCelect, an autologous cell therapy product for cartilage repair of the knee, which was the first Advanced Therapy Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA). From June 2014, the marketing and distribution rights of ChondroCelect were exclusively licensed to Sobi for the European Union (except for Finland, where it is distributed by the Finnish Red Cross Blood Service), Norway, Russia, Switzerland and Turkey, and the countries of the Middle East and North Africa. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain).